Should I buy or sell Cadrenal Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cadrenal Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CVKD shares. View CVKD analyst ratings or view top-rated stocks .

What is Cadrenal Therapeutics' stock price target for 2024?

1 brokerages have issued 1-year price targets for Cadrenal Therapeutics' shares. Their CVKD share price targets range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 468.7% from the stock's current price. View analysts price targets for CVKD or view top-rated stocks among Wall Street analysts .

How have CVKD shares performed in 2023?

Cadrenal Therapeutics' stock was trading at $4.12 at the beginning of 2023. Since then, CVKD shares have decreased by 87.2% and is now trading at $0.5275. View the best growth stocks for 2023 here .

When is Cadrenal Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024. View our CVKD earnings forecast .

When did Cadrenal Therapeutics IPO?

(CVKD) raised $7 million in an IPO on Friday, January 20th 2023. The company issued 1,400,000 shares at $5.00 per share.

Who are Cadrenal Therapeutics' major shareholders?

Cadrenal Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (7.54%). Insiders that own company stock include John Raymond Murphy and Quang X Pham. View institutional ownership trends .

Cadrenal Therapeutics Stock Price, News & Analysis (NASDAQ:CVKD)

$0.53

0.00 (0.00%)

(As of 11/27/2023 ET)

Compare

Today's Range: $0.47
▼
$0.54
50-Day Range: $0.41
▼
$0.74
52-Week Range: $0.40
▼
$6.75

Volume: 45,052 shs
Average Volume: 43,168 shs
Market Capitalization: $6.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Cadrenal Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 468.7% Upside
$3.00 Price Target
Short Interest: Healthy
0.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.76
Based on 6 Articles This Week
Insider Trading: Acquiring Shares
$75,832 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.64) to ($0.68) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Cadrenal Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Cadrenal Therapeutics has a forecasted upside of 468.7% from its current price of $0.53.
Amount of Analyst Coverage
Cadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.25% of the float of Cadrenal Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Cadrenal Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cadrenal Therapeutics has recently decreased by 63.44%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cadrenal Therapeutics does not currently pay a dividend.
Dividend Growth
Cadrenal Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CVKD.

2.1

News and Social Media Coverage

News Sentiment
Cadrenal Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Cadrenal Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 2 people have searched for CVKD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cadrenal Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $75,832.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
58.12% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 4.57% of the stock of Cadrenal Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Cadrenal Therapeutics are expected to decrease in the coming year, from ($0.64) to ($0.68) per share.

See Top Rated MarketRank™ Stocks Here

About Cadrenal Therapeutics Stock (NASDAQ:CVKD)

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

CVKD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CVKD Stock News Headlines

November 23, 2023 | americanbankingnews.com

HC Wainwright Comments on Cadrenal Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:CVKD)

November 21, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Cadrenal Therapeutics (CVKD) with Buy Recommendation

November 28, 2023 | Edge On The Street (Ad)

Americans Now Favor Gold Over Stocks as an Investment Vehicle

Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.

November 21, 2023 | americanbankingnews.com

Cadrenal Therapeutics (NASDAQ:CVKD) Now Covered by Analysts at HC Wainwright

November 9, 2023 | msn.com

Cadrenal Therapeutics reports Q3 results

November 9, 2023 | finance.yahoo.com

Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update

October 9, 2023 | finance.yahoo.com

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference

September 5, 2023 | finance.yahoo.com

Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress

November 28, 2023 | Edge On The Street (Ad)

Americans Now Favor Gold Over Stocks as an Investment Vehicle

August 30, 2023 | finance.yahoo.com

Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)

August 28, 2023 | finance.yahoo.com

Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

August 18, 2023 | seekingalpha.com

CVKD Cadrenal Therapeutics, Inc.

August 10, 2023 | finance.yahoo.com

Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update

August 1, 2023 | finance.yahoo.com

Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases

July 24, 2023 | finance.yahoo.com

Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors

July 14, 2023 | bizjournals.com

Ponte Vedra-based Cadrenal Therapeutics set to raise $7.5M

July 12, 2023 | finance.yahoo.com

Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules

July 6, 2023 | finance.yahoo.com

The 3 Hottest IPOs to Buy Before They Soar

July 4, 2023 | msn.com

Best and worst performing healthcare IPOs of 2023, so far

June 1, 2023 | finance.yahoo.com

Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston

May 10, 2023 | finance.yahoo.com

Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update

May 9, 2023 | finance.yahoo.com

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference

March 30, 2023 | finance.yahoo.com

Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update

March 9, 2023 | finance.yahoo.com

Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population

February 9, 2023 | bizjournals.com

Cadrenal celebrates IPO with bell ringing at Nasdaq

February 8, 2023 | finance.yahoo.com

Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023

February 6, 2023 | finance.yahoo.com

Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference

See More Headlines

Receive CVKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/08/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CVKD
CUSIP: N/A
CIK: 1937993
Web: www.cadrenal.com
Phone: 904-300-0701
Fax: N/A
Employees: 3
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.00
High Stock Price Target: $3.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +468.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $1.10 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -141.10%
Return on Assets: -81.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.45
Quick Ratio: 16.45

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: $0.11 per share
Price / Cash Flow: 4.99
Book Value: ($0.48) per share
Price / Book: -1.10

Miscellaneous

Outstanding Shares: 13,020,000
Free Float: 5,454,000
Market Cap: $6.87 million
Optionable: Not Optionable
Beta: N/A

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Quang X. Pham (Age 58)
Chairman & CEO
Comp: $822.17k
Mr. Matthew K. Szot CPA (Age 49)
CPA, Co-Founder & CFO
Comp: $359.61k
Dr. Douglas W. Losordo FACC (Age 65)
FAHA, M.D., Chief Medical Officer
Comp: $23.36k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CVKD Stock Analysis - Frequently Asked Questions

Should I buy or sell Cadrenal Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cadrenal Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CVKD shares.
View CVKD analyst ratings or view top-rated stocks.
What is Cadrenal Therapeutics' stock price target for 2024?: 1 brokerages have issued 1-year price targets for Cadrenal Therapeutics' shares. Their CVKD share price targets range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 468.7% from the stock's current price.
View analysts price targets for CVKD or view top-rated stocks among Wall Street analysts.
How have CVKD shares performed in 2023?: Cadrenal Therapeutics' stock was trading at $4.12 at the beginning of 2023. Since then, CVKD shares have decreased by 87.2% and is now trading at $0.5275.
View the best growth stocks for 2023 here.
When is Cadrenal Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our CVKD earnings forecast.

When did Cadrenal Therapeutics IPO?: (CVKD) raised $7 million in an IPO on Friday, January 20th 2023. The company issued 1,400,000 shares at $5.00 per share.
Who are Cadrenal Therapeutics' major shareholders?: Cadrenal Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (7.54%). Insiders that own company stock include John Raymond Murphy and Quang X Pham.
View institutional ownership trends.
How do I buy shares of Cadrenal Therapeutics?: Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CVKD) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial